ATE548376T1 - Immunsystem-modulierende peptide aus hitzeschock- proteinen und deren verwendungen - Google Patents

Immunsystem-modulierende peptide aus hitzeschock- proteinen und deren verwendungen

Info

Publication number
ATE548376T1
ATE548376T1 AT01992716T AT01992716T ATE548376T1 AT E548376 T1 ATE548376 T1 AT E548376T1 AT 01992716 T AT01992716 T AT 01992716T AT 01992716 T AT01992716 T AT 01992716T AT E548376 T1 ATE548376 T1 AT E548376T1
Authority
AT
Austria
Prior art keywords
modulation
immune
immune system
heat shock
shock proteins
Prior art date
Application number
AT01992716T
Other languages
English (en)
Inventor
Alberto Martini
Salvatore Albani
Dennis Carson
Berent Prakken
Original Assignee
Univ California
Alberto Martini
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California, Alberto Martini filed Critical Univ California
Application granted granted Critical
Publication of ATE548376T1 publication Critical patent/ATE548376T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT01992716T 2000-11-01 2001-10-31 Immunsystem-modulierende peptide aus hitzeschock- proteinen und deren verwendungen ATE548376T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24518100P 2000-11-01 2000-11-01
PCT/US2001/045344 WO2002036611A2 (en) 2000-11-01 2001-10-31 Immunomodulatory peptides derived from heat shock proteins and uses thereof

Publications (1)

Publication Number Publication Date
ATE548376T1 true ATE548376T1 (de) 2012-03-15

Family

ID=22925623

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01992716T ATE548376T1 (de) 2000-11-01 2001-10-31 Immunsystem-modulierende peptide aus hitzeschock- proteinen und deren verwendungen

Country Status (13)

Country Link
US (2) US7301005B2 (de)
EP (1) EP1355923B1 (de)
JP (1) JP4264257B2 (de)
KR (1) KR20030055295A (de)
CN (1) CN1481390B (de)
AT (1) ATE548376T1 (de)
AU (1) AU2002220038A1 (de)
BR (1) BR0115246A (de)
CA (1) CA2427572A1 (de)
EA (1) EA005821B1 (de)
IL (1) IL155610A0 (de)
MX (1) MXPA03003901A (de)
WO (1) WO2002036611A2 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006052773A2 (en) * 2004-11-07 2006-05-18 Androclus Therapeutics Inc. Treatments for demyelinating immune mediated diseases
WO2007140287A2 (en) * 2006-05-25 2007-12-06 Dr. Reddy's Laboratories, Inc. Use of biomarkers of inflammation as indicators of drug efficacy
AT504685B1 (de) * 2006-12-20 2009-01-15 Protaffin Biotechnologie Ag Fusionsproteine
US8742068B2 (en) 2007-07-06 2014-06-03 Universiteit Utrecht Holding B.V. Treatment and prevention of inflammatory diseases and autoimmune diseases
SG187201A1 (en) * 2010-07-26 2013-02-28 Qu Biolog Inc Immunogenic anti-inflammatory compositions
RU2483746C1 (ru) * 2012-05-17 2013-06-10 Федеральное государственное унитарное предприятие "Государственный научный центр "Научно-исследовательский институт органических полупродуктов и красителей" (ФГУП "ГНЦ "НИОПИК") Средство для антиагрегатной, антивоспалительной и цитопротекторной терапии
KR101632948B1 (ko) * 2014-05-13 2016-06-27 (주)케어젠 항염증, 골 형성 및 발모 촉진 활성을 갖는 펩타이드 및 이의 용도
WO2017203356A1 (en) 2016-05-25 2017-11-30 The Council Of The Queensland Institute Of Medical Research Methods of immunotherapy
CN111936166B (zh) * 2018-02-09 2024-10-22 国家科学与技术研究理事会(Conicet) 用于药物递送的免疫调节和免疫刺激多肽
GB201807831D0 (en) * 2018-05-15 2018-06-27 Univ College Cardiff Consultants Ltd Cancer Vaccine

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4732757A (en) 1978-02-06 1988-03-22 Stolle Research And Development Corporation Prevention and treatment of rheumatoid arthritis
US4683295A (en) 1984-05-24 1987-07-28 Scripps Clinic And Research Foundation Method for the preparation of anti-receptor antibodies
US4654419A (en) 1984-08-08 1987-03-31 Scripps Clinic And Research Foundation Synthetic polypeptides and antibodies related to epstein-barr virus nuclear antigen
US5116725A (en) 1984-08-08 1992-05-26 Scripps Clinic And Research Foundation Assay for Epstein-Barr virus infection with solid phase bound synthetic polypeptides
US5310732A (en) 1986-02-03 1994-05-10 The Scripps Research Institute 2-halo-2'-deoxyadenosines in the treatment of rheumatoid arthritis
EP0474764A4 (en) 1989-05-31 1992-11-19 Scripps Clinic And Research Foundation Method to treat rheumatoid arthritis
KR920703114A (ko) * 1989-07-14 1992-12-17 원본미기재 접합체 백신을 위한 시토킨 및 호르몬 운반체
US5891435A (en) 1993-04-16 1999-04-06 Research Corporation Technologies, Inc. Methods and compositions for delaying or preventing the onset of autoimmune disease
US5728385A (en) 1993-08-12 1998-03-17 Classen Immunotherapies, Inc. Method and composition for an early vaccine to protect against both common infectious diseases and chronic immune mediated disorders or their sequelae
US5773570A (en) * 1994-05-20 1998-06-30 The Regents Of The University Of California Vaccine compositions and methods useful in inducing immune protection against arthritogenic peptides involved in the pathogenesis of rheumatoid arthritis
WO1995031984A1 (en) 1994-05-20 1995-11-30 The Regents Of The University Of California Method and reagents for the treatment of rheumatoid arthritis
US5993803A (en) 1996-08-30 1999-11-30 Yeda Research And Development Co., Ltd. Method of reducing the severity of host vs graft reaction by down-regulating hsp60 autoimmunity
DE19702065C1 (de) * 1997-01-22 1998-05-20 Kurzik Dumke Ursula Dr Polyklonaler Antikörper zum Nachweis des tumorassoziierten Antigens hTid
US6007821A (en) 1997-10-16 1999-12-28 Fordham University Method and compositions for the treatment of autoimmune disease using heat shock proteins
US5992567A (en) 1999-01-29 1999-11-30 Chiu; Ping-Jan Foldable frame

Also Published As

Publication number Publication date
MXPA03003901A (es) 2004-09-10
KR20030055295A (ko) 2003-07-02
JP2004537496A (ja) 2004-12-16
WO2002036611A3 (en) 2003-08-21
BR0115246A (pt) 2005-04-26
AU2002220038A1 (en) 2002-05-15
EP1355923B1 (de) 2012-03-07
JP4264257B2 (ja) 2009-05-13
CA2427572A1 (en) 2002-05-10
EA005821B1 (ru) 2005-06-30
US7301005B2 (en) 2007-11-27
IL155610A0 (en) 2003-11-23
EA200300438A1 (ru) 2003-12-25
WO2002036611A2 (en) 2002-05-10
EP1355923A2 (de) 2003-10-29
CN1481390B (zh) 2010-12-22
CN1481390A (zh) 2004-03-10
US20030031679A1 (en) 2003-02-13
US20080187550A1 (en) 2008-08-07

Similar Documents

Publication Publication Date Title
ATE226635T1 (de) Clostridium perfringens impfstoffe
Singh et al. Mucosal immunization with HIV-1 gag DNA on cationic microparticles prolongs gene expression and enhances local and systemic immunity
Ciabattini et al. Oral priming of mice by recombinant spores of Bacillus subtilis
WO2008057235A3 (en) Enhanced immunogenicity of tumor associated antigens by addition of alphagal epitopes
CY1113379T1 (el) Πεπτιδια κdr και εμβολια που τα περιλαμβανουν
GEP20022695B (en) Moraxella Catarrhalis Outer Membrane Protein-106 Polypeptide, Gene Sequence and Uses Thereof
ATE548376T1 (de) Immunsystem-modulierende peptide aus hitzeschock- proteinen und deren verwendungen
BR0210225A (pt) Holotoxina do cólera imunogênica mutante, composição imunogênica, método para realçar a resposta imune de um hospedeiro vertebrado a um antìgeno, sequência de dna isolada e purificada, molécula de ácido nucleico, célula hospedeira, método para produzir uma holotoxina do cólera imunogênica mutante, e, uso de uma holotoxina do cólera mutante
Le Moigne et al. Flagellin as a good carrier and potent adjuvant for Th1 response: study of mice immune response to the p27 (Rv2108) Mycobacterium tuberculosis antigen
EP1536006A4 (de) Krebsantigene und deren nutzung
Lee et al. Vaccination and mucosal responses to Helicobacter pylori infection.
FR2781158B1 (fr) Nouvelles proteines modifiees immunogenes non immunosuppressives, leur procede de preparation et leurs applications
NZ526879A (en) Genes and proteins, and their use
Eng et al. PCEP enhances IgA mucosal immune responses in mice following different immunization routes with influenza virus antigens
Chin et al. Manipulating systemic and mucosal immune responses with skin-deliverable adjuvants
Falcone et al. Systemic and mucosal immunity to respiratory syncytial virus induced by recombinant Streptococcus gordonii surface-displaying a domain of viral glycoprotein G
WO2003063786A3 (en) Methods and composition for delivering nucleic acids and/or proteins to the respiratory system
Luongo et al. Immunomodulation of gut-associated lymphoid tissue: current perspectives
De Magistris Zonula occludens toxin as a new promising adjuvant for mucosal vaccines
EP1090995A3 (de) Mycoplasma hyopneumoniae Antigen MHP3, dafür kodierendes Gen und Ihre Verwendungen
Ma et al. The novel combinations of CTB, CpG, and aluminum hydroxide significantly enhanced the immunogenicity of clumping factor A 221-550 of Staphylococcus aureus
Srivastava et al. Proteolytically inactive per a 10 allergen of Periplaneta americana modulates Th2 response and enhances IL-10 in mouse model
Jun et al. Sublingual immunization with adenovirus F protein-based vaccines stimulates protective immunity against botulinum neurotoxin A intoxication
Maubant et al. Adjuvant properties of cytosine-phosphate-guanosine oligodeoxynucleotide in combination with various polycations in an ovalbumin-vaccine model
HUT77422A (hu) Humán dezoxiribonukleáz I variánsok